| Active substance | enfortumab vedotin |
| Holder | Astellas Pharma Global Development, Inc. |
| Status | closed |
| Indication | locally advanced or metastatic urothelial cancer in patients who have previously received a platinum-containing chemotherapy and a programmed death receptor 1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitor |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 27/02/2023 |